Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleuce…
Warm Autoimmune Hemolytic Anemia (WAIHA)ITP - Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia+1 more
Estimated
~$10 – $8,750
CRISPR Therapeutics AGNCT07549698
Phase 2
A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)
The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and auto…
Chronic Immune ThrombocytopeniaAutoimmune Hemolytic Anemia
Estimated
~$10 – $8,750
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07603557